Pneumonia severity index: Difference between revisions
Jump to navigation
Jump to search
imported>Joe Quick m (subpages) |
imported>Robert Badgett No edit summary |
||
| Line 3: | Line 3: | ||
The accuracy of the PSI has been independently validated by other researchers.<ref name="pmid15808136">{{cite journal |author=Aujesky D, Auble TE, Yealy DM, ''et al'' |title=Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia |journal=Am. J. Med. |volume=118 |issue=4 |pages=384-92 |year=2005 |pmid=15808136 |doi=10.1016/j.amjmed.2005.01.006}}</ref> | The accuracy of the PSI has been independently validated by other researchers.<ref name="pmid15808136">{{cite journal |author=Aujesky D, Auble TE, Yealy DM, ''et al'' |title=Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia |journal=Am. J. Med. |volume=118 |issue=4 |pages=384-92 |year=2005 |pmid=15808136 |doi=10.1016/j.amjmed.2005.01.006}}</ref> | ||
Patients with PSI Risk groups I-III can usually be treated as an outpatient.<ref name="pmid15684204">{{cite journal |author=Carratalà J, Fernández-Sabé N, Ortega L, ''et al'' |title=Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients |journal=Ann. Intern. Med. |volume=142 |issue=3 |pages=165–72 |year=2005 |month=February |pmid=15684204 |doi= |url= |issn=}}</ref> | |||
A [[randomized controlled trial]] found that use of the PSI to guide management of [[community acquired pneumonia]] improved medical care by reducing resource consumption without reducing quality of care.<ref name="pmid10683053">{{cite journal |author=Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG |title=A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin |journal=JAMA |volume=283 |issue=6 |pages=749-55 |year=2000 |pmid=10683053 |doi=}}</ref> | A [[randomized controlled trial]] found that use of the PSI to guide management of [[community acquired pneumonia]] improved medical care by reducing resource consumption without reducing quality of care.<ref name="pmid10683053">{{cite journal |author=Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG |title=A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin |journal=JAMA |volume=283 |issue=6 |pages=749-55 |year=2000 |pmid=10683053 |doi=}}</ref> | ||
Revision as of 14:49, 8 January 2009
The pneumonia severity index (PSI) is a clinical prediction rule to estimate the probability of complications among patients with community acquired pneumonia.[1]
The accuracy of the PSI has been independently validated by other researchers.[2]
Patients with PSI Risk groups I-III can usually be treated as an outpatient.[3]
A randomized controlled trial found that use of the PSI to guide management of community acquired pneumonia improved medical care by reducing resource consumption without reducing quality of care.[4]
The pneumonia severity index has been compared to the CURB-65 in predicting mortality.[2]
References
- ↑ Fine MJ, Auble TE, Yealy DM, et al (1997). "A prediction rule to identify low-risk patients with community-acquired pneumonia". N. Engl. J. Med. 336 (4): 243–50. PMID 8995086. [e]
- ↑ 2.0 2.1 Aujesky D, Auble TE, Yealy DM, et al (2005). "Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia". Am. J. Med. 118 (4): 384-92. DOI:10.1016/j.amjmed.2005.01.006. PMID 15808136. Research Blogging.
- ↑ Carratalà J, Fernández-Sabé N, Ortega L, et al (February 2005). "Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients". Ann. Intern. Med. 142 (3): 165–72. PMID 15684204. [e]
- ↑ Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG (2000). "A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin". JAMA 283 (6): 749-55. PMID 10683053. [e]